Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Neoadjuvant study of Chemotherapy versus EndocriNe Therapy in postmenopausal patients with primary breast cancer

Trial Profile

Neoadjuvant study of Chemotherapy versus EndocriNe Therapy in postmenopausal patients with primary breast cancer

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 10 Nov 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Letrozole (Primary) ; Cyclophosphamide; Docetaxel; Epirubicin; Fluorouracil
  • Indications Breast cancer
  • Focus Therapeutic Use
  • Acronyms Neo-CENT

Most Recent Events

  • 30 Jan 2014 Accrual to date is 110% according to UKCRN database record.
  • 09 Aug 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
  • 31 May 2012 Additional trial locations (Northern Ireland, Scotland) added as reported by United Kingdom Clinical Research Network.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top